Most of the attention right now is on vaccines, but vaccines are only part of the battle against COVID-19. Dr. Mark DiNubile, Chief Medical Officer at BioAegis, joins KYW Newsradio In Depth to talk about what’s out there right now, the science behind COVID-19 treatments, and why he believes so strongly that gelsolin therapy can …
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that studies from three independent groups of investigators, including the NIH, have reported that low levels of gelsolin are associated with severity and organ …
No drug-related safety signals identified by the independent Data and Safety Monitoring Board. MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced that it has expanded its clinical trial in severe COVID-19 …
The leadership team of BioAegis Therapeutics will share their experiences this year as they reframed their strategy to address the COVID-19 threat to their employees and hustled to initiate a COVID-19 clinical trial for severe COVID-19 patients. When: Thursday, August 20, 2020 12:00 p.m. – 1:00 p.m. EDT Where: Online (GoToWebinar) Contact: WIB-Metro New York …
BioAegis has been selected as a featured company in the upcoming BioNJ COVID-19 Rapid Fire Research Showcase. Our Chief Executive Officer and Co-founder, Dr. Susan Levinson, will present our goundbreaking recombinant human plasma gelsolin (rhu-pGSN) therapy. WHEN: Friday, June 5, 2020, 9:00 a.m. – 10:00 a.m. Register Now
Mr. Barno is a Capital Advisor and Technology Entrepreneur, and former Executive at Xerox Corporation, IBM, and Institutional Portfolio Manager at UBS Paine Webber. He has advised many Fortune 500 companies including Centel, Hartford Group, Apple Computer, IBM, Microsoft, Boeing, and for the Government of Canada. He founded Press Access ( acquired by Lexis-Nexis) and …
Steven Cordovano brings to BioAegis a sophisticated market perspective and broad investor network gained through years of investment experience as a highly successful fund manager. He has worked in finance and portfolio management for 25 years. Prior to BioAegis, Mr. Cordovano was a Partner with Trivalent Partners, where he assisted emerging growth companies in developing …
VP, Corporate Development and Communications, Steven Cordovano Read More »
Lester Kobzik is a professor emeritus of Pathology at the Harvard Medical School and the Harvard T. H. Chan School of Public Health. His research interests center on lung disease and how the lung defends itself against inhaled toxic and infectious challenges. His work has characterized scavenger receptors on lung macrophages and how they function …
Nineteen-time Emmy-winner John Stossel was hailed by The Dallas Morning News as “the most consistently thought-provoking TV reporter of our time.” Stossel began his career as a business-bashing consumer reporter calling for government regulation. But when he saw that regulation causes new problems, he woke up and started reporting on wonderful things that free markets …
Mark J. DiNubile, MD FIDSA, has recently joined BioAegis Therapeutics as our Chief Medical Officer to propel us forward into late-stage clinical development. He brings to the table the rare combination of clinical and research expertise along with broad pharmaceutical industry experience, coupled with his long-standing dedication to elucidating the clinical utility of plasma gelsolin. …
Chief Medical Officer, Mark J. DiNubile, MD, FIDSA Read More »
LOCATION:
BioAegis Therapeutics
North Brunswick, NJ
MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com
INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com
©2023 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use